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Background: Elderly heart failure (HF) patients frequently have multiple comorbidities. The prognostic
impact of combined comorbidities is poorly quantified in these patients. We assessed the impact of comor-
bidities on 3-year mortality in geriatric outpatients with newly diagnosed HF.
Methods and Results: Of 93 geriatric outpatients with HF (mean age 82.7 years, 36.6% men), 52 patients
(55.9%) died within 3 years after HF was diagnosed. Comorbidity was measured with the Charlson Comor-
bidity Index (CCI). Age- and gender-adjusted hazard ratio (HR) for 3-yearmortalitywas 1.6 (95%confidence
interval [CI] 0.9e3.2) for patients with 3e4 CCI points and 3.2 (95% CI 1.5e6.8) for those withO4 CCI
points, compared with 1e2 CCI points. After adjustment for age, gender, left ventricular ejection fraction
(LVEF), and N-terminal proeB-type natriuretic peptide, CCI remained predictive of death (CCI 3e4: HR
1.5 (95% CI 0.7e2.9); CCIO4: HR 4.0 (95% CI 1.9e8.8)). In addition to age and gender, the c-statistics
for CCI and LVEF were similar (0.63 [95% CI 0.55e0.70] and 0.64 [95% CI 0.56e0.72], respectively).
Conclusions: The majority of geriatric outpatients with new HF die within 3 years. Comorbidity, summa-
rized in the CCI, is the strongest independent predictor of mortality. (J Cardiac Fail 2012;18:47e52)
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lowing acute cardiac events leads to an increased preva-
lence of heart failure, especially in the elderly.1,2 Survival
in geriatric patients with heart failure is generally poor.
Elderly heart failure patients have a wide range of both car-
diovascular and noncardiovascular comorbidities, that may
influence prognosis.3,4 Although the impact of several
diseases on prognosis in heart failure patients has been
established,1,5 predominantly in hospitalized patients,6 the
impact of combinations of concomitant diseases in geriatric
patients is largely unknown, especially in the large group of
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Open access under the Elsevier OA license.Index (CCI) is an extensively studied and validated instru-
ment to assess comorbidity that has been shown to predict
prognosis in a variety of patient groups (eg, patients with
cancer, pneumonia, or admitted to internal wards).7e9 In el-
derly heart failure patients, other than 2 studies addressing
short-term (1-year) or long-term (12-year) mortality, the ef-
fect of comorbidity, as measured with the CCI, on the prog-
nosis of heart failure has not been addressed.10,11 We
determined the impact of comorbidity, measured with the
CCI, on 3-year mortality in geriatric outpatients with newly
diagnosed heart failure.Methods
Study Population
Patients referred, for a variety of reasons, to the geriatric outpa-
tient clinic of 2 regional hospitals in The Netherlands (Elkerliek
Hospital, Helmond, and Meander Medical Center, Amersfoort)
who presented with symptoms of breathlessness, fatigue, ankle
swelling, or any combination of these were eligible, as described
in detail elsewhere.12 Only patients with newly diagnosed heart
failure in whom the symptoms had increased gradually before
the diagnosis (so-called ‘‘slow-onset’’ heart failure) were in-
cluded. Patients with acute-onset heart failure requiring emer-
gency admission were excluded. Briefly, 206 geriatric
outpatients suspected of new heart failure by a geriatrician
48 Journal of Cardiac Failure Vol. 18 No. 1 January 2012underwent a comprehensive standardized diagnostic work-up. The
presence or absence of heart failure was established by an out-
come panel according to the diagnostic criteria for heart failure
of the European Society of Cardiology, using all available diag-
nostic information.13 Each of the participants, or their representa-
tives in case of impaired cognition, gave his or her written consent.
Patients were recruited between July 2003 and July 2007. The
study was approved by the Medical Ethical Committees of both
participating hospitals.
Comorbidity
We used the CCI, which assigns points for several medical con-
ditions, to evaluate the severity of comorbidity with a score rang-
ing from 1 (only heart failure present) to 30 (extensive
comorbidity).7 All diagnoses obtained from the general practi-
tioner’s referral letter, letters of other specialists retrieved from
the hospital information system, and diagnoses established by
the geriatricians within 2 months after the initial visit were re-
garded to be comorbidity. The presence or absence of heart failure
according to the outcome panel was established before calculating
the CCI.
Outcome
The outcome of the study was all-cause mortality within 3 years
after heart failure was diagnosed. Information on vital status was
obtained from the hospital information system or from the pa-
tients’ general practitioners. Follow-up data were collected be-
tween July 2003 and July 2010. One patient without heart
failure was lost to follow-up after the first year and was considered
to have withdrawn alive as of the last date of follow-up.
Data Analysis
Data with a normal distribution were summarized as means with
standard deviations (SD). Data with a skewed distribution were
summarized as medians with interquartile ranges (25th-75th per-
centiles). To obtain a normal distribution, N-terminal proeB-type
natriuretic peptide (NT-proBNP) values were logarithmically
transformed. Left ventricular ejection fraction (LVEF) was catego-
rized in patients with LVEF!35%, 35%e45%, andO45%. CCI
score was categorized in subjects with a CCI score of 1e2, 3e4,
and O4 points.14 A Cox proportional hazards analysis was per-
formed to calculate differences in survival between patients with
and without heart failure and differences between patients with
heart failure due to impaired (n 5 49) and preserved (n 5 44)
LVEF after adjusting for age and gender. The ability of established
determinants (ie, age, gender, LVEF, and NT-proBNP) and CCI to
discriminate between patients who died and who remained alive
was estimated with the use of the c-statistic, which reflects the
area under the receiver operating characteristic curve.15 The c-sta-
tistic can range from 0.5 (no discrimination, like flipping a coin) to
1.0 (perfect discrimination).16 Multivariate proportional hazards
analysis was performed to determine the independent value of co-
morbidity after adjusting for ‘‘established’’ determinants of mortal-
ity in heart failure. For continuous variables, the assumption of
linearity was assessed with the use of restrictive cubic splines.15
The reproducibility (intrarater agreement) of the CCI, evaluated
by retesting 21 cases (10.2% of total population), was good, with
an intraclass correlation coefficient of 0.95 (95% confidence inter-
val [CI] 0.89e0.98). None of the predictors had missing values.
Data were analyzed with the use of SPSS (version 17.0 for
Windows; SPSS; Chicago, IL, USA), and R (version 2.8.1; RFoundation for Statistical Computing, Vienna, Austria [http://
www.R-project.org]) software.
Results
Ninety-three geriatric outpatients with newly diagnosed,
‘‘slow-onset’’ heart failure (63.4% female; mean age
82.7 6 5.3 years) were included (Table 1). Three-year
all-cause mortality was much higher (55.9%) in geriatric
patients with newly diagnosed heart failure than in those
without (28.3%; crude hazard ratio [HR] 2.6 [95% CI
1.7e4.1]; age and gender adjusted HR 2.2 [95% CI
1.4e3.4]; Fig. 1). Three-year mortality did not differ be-
tween patients with systolic heart failure) LVEF !45%)
and those with heart failure with preserved ejection fraction
(HFPEF): 59.2% and 52.3%, respectively; crude HR 1.3
(95% CI 0.7e2.2); HR adjusted for age and gender 1.3
(95% CI 0.7e2.3).
Mortality increased with higher CCI score from 42.9% in
the 35 patients with a CCI of 1e2 to 57.1% in those with
CCI 3e4 (n 5 42) and 81.3% in those with CCI O4
(n 5 16). Compared with CCI 1e2, HR for death within
3 years was 1.6 (95% CI 0.8e3.0) for patients with CCI
3e4 and 3.3 (95% CI 1.5e6.9) for patients with CCI O4
(Table 2). The CCI remained predictive of mortality after
adjustment for age and gender (CCI 3e4: HR 1.6 [95%
CI 0.9e3.2]; CCI O4: HR 3.2 [95% CI 1.5e6.8]; Fig. 2).
In addition to age and gender, the c-statistic was 0.63 for
CCI (95% CI 0.55e0.70), 0.64 (95% CI 0.56e0.72) for
LVEF, and 0.59 (95% CI 0.50e0.67) for NT-proBNP.
Combining these determinants improved the c-statistic to
0.69 (95% CI 0.62e0.76). The CCI remained predictive
of mortality after adjustment for age, gender, LVEF, and
NT-proBNP (CCI 3e4: HR 1.5 [95% CI 0.7e2.9];
CCI O4: HR 4.0 [95% CI 1.9e8.8]).
Discussion
More than one-half of 93 (n 5 52; 55.9%) geriatric out-
patients with newly diagnosed ‘‘slow-onset’’ heart failure
(ie, gradually increasing symptoms of heart failure not re-
quiring hospital admission) died within 3 years after estab-
lishing the diagnosis. Mortality increased with more
extensive comorbidity, as assessed with the CCI, 3-year
mortality being 81.3% in heart failure patients with a CCI
scoreO4. The CCI was the strongest independent predictor
of mortality.
Three-year mortality in our group of geriatric outpatients
with new heart failure, being twice as high compared with
those without heart failure, reflects the poor prognosis of
heart failure as demonstrated earlier in the general popula-
tion and in elderly hospitalized patients.17,18 Because el-
derly heart failure patients are likely to have multiple
cardiovascular and noncardiovascular comorbidities that in-
fluence prognosis,4,19 we intended to determine the prog-
nostic value of comorbidity ‘‘as a whole’’ rather than
focusing on the effect of individual concomitant diseases
Table 1. Baseline Characteristics of Geriatric Outpatients
with Heart Failure (n 5 93)
Variable
Age, y 82.7 6 5.3
Male sex 34 (36.6)
Cardiovascular comorbidity and risk factors
Ischemic heart disease, n (%) 25 (26.9)
Myocardial infarction, n (%) 17 (18.3)
Angina pectoris, n (%) 8 (8.6)
Vascular comorbidity, n (%) 55 (59.1)
Hypertension, n (%) 39 (41.9)
Diabetes mellitus, n (%) 25 (26.9)
CVA or TIA, n (%) 20 (21.5)
Atrial fibrillation, n (%) 36 (38.7)
Overweight, n (%) 31 (35.6)
Current smoker, n (%) 18 (19.4)
Noncardiovascular comorbidity
COPD, n (%) 25 (26.9)
Cognitive impairment, n (%) 25 (26.9)
Malignancies, n (%) 15 (16.1)
Drugs
Loop diuretic, n (%) 38 (40.9)
ACEI/ARBs, n (%) 35 (37.6)
b-Blockers, n (%) 26 (28.0)
Digitalis, n (%) 22 (23.7)
Aldosterone antagonists, n (%) 10 (10.8)
Drugs, number 6 (5e8)
NT-proBNP, pg/mL 2,295 (791e5,543)
eGFR MDRD, mL min1 1.73 m2 58 6 20
CCI, points 3 (2e4)
LVEF, % 43 6 14
Data are presented as number (%) of patients, mean 6 SD, or median
(25the75th percentiles). Ischemic heart disease: presence of myocardial
infarction, angina pectoris, coronary artery bypass grafting, or percutane-
ous coronary intervention; overweight: body mass index 25e30 kg/m2;
vascular comorbidity: including hypertension, diabetes mellitus, stroke,
and peripheral artery disease. CVA, cerebrovascular accident; TIA, tran-
sient ischemic attack; COPD, chronic obstructive pulmonary disease;
ACEI, angiotensin-converting enzyme inhibitor; ARBs, angiotensin II re-
ceptor blockers; NT-proBNP, N-terminal pro-B-type natriuretic peptide;
eGFR MDRD, estimated glomerular filtration rate according to the Modi-
fication of Diet in Renal Disease study group equation; CCI, Charlson Co-
morbidity Index; LVEF, left ventricular ejection fraction.
Fig. 1. Cox survival curves for geriatric patients according to the
presence and type of heart failure, adjusted for age and gender.
Thin solid line: heart failure absent; thick solid line: heart failure
present; thin dashed line: heart failure with preserved ejection
fraction; thick dashed line: systolic heart failure.
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stroke, or dementia). To achieve this goal we used the
CCI, a validated instrument that has been shown to predict
nonsudden death in heart failure,20 mortality, or lung trans-
plantation within the first year after admission for right-
sided heart failure in pulmonary arterial hypertension21
and in-hospital mortality among elderly patients admitted
to an internal medicine ward.9 The strong relation between
CCI and mortality testifies to the importance of various co-
morbidities in geriatric outpatients with heart failure. Our
patient population (mean age 82.7 years; median drugs
used, 6) differed from that in the study of 125 heart failure
patients that failed to demonstrate an impact of CCI on
12-year mortality.11 The mean age of those patients was
74 years, and the fact that they were using only 2 medica-
tions on average suggests limited comorbidity. Further-
more, it is possible that the CCI does not predict 12-year
mortality very well, because!50% of heart failure patients
tend to survive 5 years, regardless of the extent of their
comorbidities.1Several risk models to help physicians in estimating
prognosis in heart failure patients exist, eg, the Seattle
Heart Failure Model (SHFM)22 and the scoring systems
of the Enhanced Feedback for Effective Cardiac Treatment
(EFFECT) study6 and the Acute Decompensated Heart
Failure Registry (ADHERE).23 The SHFM predicts 5-year
mortality based on information obtained from participants
with severe systolic heart failure (median age 65 years,
24% women) of the Prospective Randomized Amlodipine
Survival Evaluation (PRAISE1) study.24 The EFFECT
study included patients (mean age 76.3 years, 50.5%
women) admitted with acute heart failure to determine
30-day and 3-year mortality, and the ADHERE registry de-
termined in-hospital mortality in patients (mean age 72.4
years, 52% women) admitted with acute heart failure.25
Ours is the first study to determine the prognostic impact
of comorbidity in elderly heart failure outpatients (mean
age 82.7 years, 63.4% women) not requiring hospitaliza-
tion, including both systolic heart failure and HFPEF. In
contrast to the 3 established risk models, we included mea-
surements of natriuretic peptides, that are known to be
important predictors in heart failure. Renal function is im-
portant in determining the prognosis of heart failure.1,5 In
our patient group, all 7 patients with an estimated glomer-
ular filtration rate!30 mL min1 1.73 m2 died within 86
weeks after heart failure was diagnosed (data not shown).
Unfortunately, the CCI uses serum creatinine to estimate re-
nal function, rather than the glomerular filtration rate ac-
cording to the Modification of Diet in Renal Disease
study group equation, which is more accurate in elderly pa-
tients.26 The CCI defines moderate or severe renal disease
as serum creatinine of $3 mg/dL (265 mmol/L) which
was present in only 1 patient, who died within 12 weeks.
It is imaginable that the CCI underestimates the severity
of renal dysfunction in elderly patients.
Table 2. Three-year mortality in 93 geriatric outpatients with heart failure in relation to established determinants and Charlson
Comorbidity Index (CCI)





Adjusted for Age, Gender,
LVEF, NT-proBNP, and CCI
Age, y 82.4 6 5.7 82.9 6 5.1 1.1 (0.7e1.9) 1.2 (0.7e2.1) 1.3 (0.7e2.4)
Male sex 13 (31.7) 21 (40.4) 1.3 (0.8e2.3) 1.4 (0.8e2.4) 1.3 (0.7e2.4)
LVEF
O45% 21 (51.2) 23 (44.2) e e e
35%e45% 14 (34.1) 9 (17.3) 0.7 (0.3e1.5) 0.7 (0.3e1.5) 0.6 (0.2e1.3)
!35% 6 (14.6) 20 (38.5) 2.0 (1.1e3.7) 2.2 (1.1e4.1) 2.1 (1.0e4.7)
NT-proBNP, pg/mL 1,883 (760e3,507) 2,925 (851e7,500) 1.2 (0.9e1.5) 1.2 (1.0e1.6) 1.1 (0.8e1.4)
CCI
1e2 points 20 (48.8) 15 (28.8) e e e
3e4 points 18 (43.9) 24 (46.2) 1.6 (0.8e3.0) 1.6 (0.9e3.2) 1.5 (0.7e2.9)
O4 points 3 (7.3) 13 (25.0) 3.3 (1.5e6.9) 3.2 (1.5e6.8) 4.0 (1.9e8.8)
Hazard ratio (HR) of CCI 3e4 and O4 points compared with CCI 1e2 points; HR of LVEF 35%e45% and !35% compared with LVEF O45%. HR
increases per 10 years of age and per ln NT-proBNP. CI, confidence interval; other abbreviations as in Table 1.
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have been identified,1,27 of which age, gender, and severity
of heart failure (reflected in LVEF and NT-proBNP) are gen-
erally considered to be the ‘‘established’’ determinants. Of
these four established determinants, only LVEF!35% influ-
enced prognosis. The observation that male gender does not
predictmortality in geriatric patientswith heart failure is con-
sistent with earlier studies in the elderly.28 In contrast with
earlier studies, neither age nor NT-proBNP predicted
3-year mortality in the present group of elderly heart failure
patients (mean age 82.7 years) with high NT-proBNP levels
(median 2,295 pg/mL). The impact of ejection fraction was
modest; mortality rates did not differ between patients with
systolic heart failure (LVEF!45%) and those with HFPEF.
The observation that mortality was higher in patients with
LVEF!35% is in line with the results of the recently pub-
lished report of the Meta-analysis Global Group in Chronic
Heart Failure (MAGGIC).29Fig. 2. Cox survival curves for geriatric patients with heart failure
according to Charlson Comorbidity Index (CCI), adjusted for age
and gender. Thin solid line: CCI 1e2 points; thin dashed line: CCI
3e4 points; thick solid line: CCI O4 points.Most prognostic studies in heart failure to date were per-
formed in patients with known heart failure,11 eg, when ad-
mitted for decompensated heart failure,10,18,19 and in
general population samples screened for the prevalence of
heart failure.17 In these studies the actual duration of heart
failure can vary appreciably. In daily practice, however,
physicians establish a diagnosis, directly followed by an as-
sessment (implicitly or explicitly) of the prognosis of the
individual patient, to determine the optimal treatment strat-
egy taking into account both life expectancy and quality of
life. The major strength of our study is that we determined
prognosis in patients with newly diagnosed heart failure re-
flecting everyday practice, which only few studies have
done before.30,31 Another strength is that we studied elderly
outpatients with a wide range of comorbidity, who are gen-
erally excluded from clinical trials32 but who are frequently
treated by general practitioners, geriatricians, internists, and
cardiologists.33 As such this is the first prognostic study of
geriatric outpatients with newly diagnosed heart failure
(mean age 82.7 years, 63.4% female) with a wide range
of both cardiovascular and noncardiovascular comorbidity.
Although the results in our study may not come as a sur-
prise, they have not been established before in this
population.
The main limitation of our study relates to the small
number of patients (n 5 93) with heart failure, resulting
in a lack of power to analyze multiple determinants of prog-
nosis. Elderly patients with multiple comorbidities and with
newly detected heart failure had a poor prognosis. This rai-
ses the question of whether this is attributable to an inherent
poor prognosis in these patients or, at least in part, to poor
adherence to evidence-based heart failure medication fol-
lowing the diagnosis, albeit that evidence from randomized
trials on the efficacy of heart failure therapy in these pa-
tients is very limited. However, no detailed information
on the use of heart failure medication following the diagno-
sis was available in this study.
Thist study shows that the prognosis of geriatric outpa-
tients with newly diagnosed heart failure is determined to
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a large extent by the severity of concomitant diseases. Ex-
plicitly taking comorbidity into consideration (eg, by means
of the CCI) will facilitate treatment decisions and discus-
sing of the various options with elderly heart failure pa-
tients and their caregivers. In those with a high CCI (and
thus with a limited life expectancy), the focus is likely to
be on symptom relief per se (eg, by diuretics), whereas in
those with a low CCI, in addition to relief of symptoms,
aiming to improve prognosis, eg, by initiating and up-
titrating beta-blockers and angiotensin-converting enzyme
inhibitors, could be a treatment goal.
In conclusion, the majority of geriatric outpatients with
newly diagnosed heart failure not requiring hospital admis-
sion die within 3 years after establishing the diagnosis. Co-
morbidity, as summarized in the CCI, is the strongest
independent predictor of 3-year mortality. It follows that
routine application of the CCI may be of help in adequately
managing this group of patients.
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